% | $
Quotes you view appear here for quick access.

Vertex Pharmaceuticals Incorporated Message Board

  • mynameissteve258 mynameissteve258 Apr 19, 2013 12:51 PM Flag

    Wall Street : Wells Fargo Upgrades to Outperform $94 PT.

    Analysts: PC Decline Hurts Microsoft’s Outlook and 2 Other Research Notes To Look Into
    By Justin Lloyd-Miller | More Articles
    April 19, 2013
    Page 2 of 3view all
    Vertex (NASDAQ:VRTX): After positive results from Vertex’s Pase II trial of the Kalydeco/VX-661 combo treatment for cystic fibrosis, Wells Fargo maintains that the data should improve the risk profile of the company’s entire cystic fibrosis franchise. The firm raised its valuation on the shares to $94, up from $62-$64, and maintains an Outperform rating.

81.90-6.30(-7.14%)Jun 24 4:00 PMEDT